ArticleGut and liver2011
Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.
Article in Gut and liver, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 88 citations in OpenAlex.
- Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention.Alimentary pharmacology & therapeutics · 2013Trial
- Economic Evaluations of Non-Pharmacological Interventions for Treating Disorders of Gut-Brain Interaction: A Scoping Review.PharmacoEconomics · 2025Article
- The role of the tryptophan metabolites in gut microbiota-brain axis and potential treatments: a focus on ischemic stroke.Frontiers in pharmacology · 2025Review
- 2-Amino-Molecules (Basel, Switzerland) · 2024Article
- Getting the guts to expand stroke treatment: The potential for microbiome targeted therapies.CNS neuroscience & therapeutics · 2023Review
- A double-blind randomized clinical trial ofResearch in pharmaceutical sciences · 2023Article
- Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study.Digestive diseases and sciences · 2022Article
- Parkinson's disease constipation effect of electroacupuncture at ST25 through colonic motility and enteric neuropathology.Frontiers in neurology · 2022Article
- Comparison of fluoxetine and duloxetine hydrochloride therapeutic effects on patients with constipation-predominant irritable bowel syndrome.Gastroenterology and hepatology from bed to bench · 2022Article
- Standardizing and optimizing acupuncture treatment for irritable bowel syndrome: A Delphi expert consensus study.Integrative medicine research · 2021Article
- Article
- The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial.Journal of neurogastroenterology and motility · 2020Article
- Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.Digestive diseases (Basel, Switzerland) · 2020Review
- The Efficacy of Acceptance and Commitment Therapy (ACT) Matrix on Depression and Psychological Capital of the Patients with Irritable Bowel Syndrome.Open access Macedonian journal of medical sciences · 2019Article
- Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: Results from patient and healthcare professional surveys.United European gastroenterology journal · 2018Article
- TummyTrials: A Feasibility Study of Using Self-Experimentation to Detect Individualized Food Triggers.Proceedings of the SIGCHI conference on human factors in computing systems. CHI Conference · 2017Article
- Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management.Healthcare (Basel, Switzerland) · 2017Review
- Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.Gut and liver · 2017Review
- Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.Therapeutic advances in gastroenterology · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by episodic abdominal pain or discomfort in association with altered bowel habits (diarrhea and/or constipation). Other gastrointestinal symptoms, such as bloating and flatulence, are also common. A variety of factors are believed to play a role in the development of IBS symptoms, including altered bowel motility, visceral hypersensitivity, psychosocial stressors, altered brain-gut interactions, immune activation/low grade inflammation, alterations in the gut microbiome, and genetic factors. In the absence of biomarkers that can distinguish between IBS subgroups on the basis of pathophysiology, treatment of this condition is predicated upon a patient's most bothersome symptoms. In clinical trials, effective therapies have only offered a therapeutic gain over placebos of 7-15%. Evidence based therapies for the global symptoms of constipation predominant IBS (IBS-C) include lubiprostone and tegaserod; evidence based therapies for the global symptoms of diarrhea predominant IBS (IBS-D) include the probiotic Bifidobacter infantis, the nonabsorbable antibiotic rifaximin, and alosetron. Additionally, there is persuasive evidence to suggest that selected antispasmodics and antidepressants are of benefit for the treatment of abdominal pain in IBS patients. Finally, several emerging therapies with novel mechanisms of action are in development. Complementary and alternative medicine therapies including probiotics, herbal therapies and acupuncture are gaining popularity among IBS sufferers, although concerns regarding manufacturing standards and the paucity of high quality efficacy and safety data remain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.